Advanced search
Publication Cover
Scandinavian Journal of Urology Volume 54, 2020 - Issue 2
Journal homepage
6,165
Views
33
CrossRef citations to date
0
Altmetric
Articles

Survival in patients diagnosed with castration-resistant prostate cancer: a population-based observational study in Sweden

Markus AlyDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; ;Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; ;Department of Urology, Karolinska Institutet, Stockholm, Sweden; Correspondence[email protected]
View further author information
,
Amy LevalDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; ;Janssen Global Services, Stockholm, Sweden; View further author information
,
Frida SchainJanssen Global Services, Stockholm, Sweden; ;Schain Research AB, Stockholm, Sweden; ;Department of Medicine, Karolinska Institutet, Stockholm, Sweden; View further author information
,
Johan LiwingJanssen Global Services, Stockholm, Sweden; ;Department of Medicine, Karolinska Institutet, Stockholm, Sweden; View further author information
,
Joe LawsonDepartment of Oncology, Janssen Research and Development, Raritan, NJ, USA; View further author information
,
Emese VágóJanssen Cilag Kft, Budapest, Hungary; View further author information
,
Tobias NordströmDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; ;Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden; ORCID Iconhttp://orcid.org/0000-0003-4915-7546View further author information
ORCID Icon,
Therese M.-L. AnderssonDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; View further author information
,
Erik SjölandDepartment of Oncology, Janssen Research and Development, Raritan, NJ, USA; View further author information
,
Chen WangDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; View further author information
,
Sandra ElorantaDepartment of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden; View further author information
&
Olof AkreDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; ;Department of Pelvic Cancer, Karolinska University Hospital, Stockholm, SwedenORCID Iconhttp://orcid.org/0000-0002-3750-3029View further author information
ORCID Icon show all
Pages 115-121 | Received 31 Dec 2019, Accepted 29 Feb 2020, Published online: 08 Apr 2020

References

  • Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–386.
  • Donovan MJ, Hamann S, Clayton M, et al. Systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy. JCO. 2008;26(24):3923–3929.
  • Smith MR, Kabbinavar F, Saad F, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. JCO. 2005;23(13):2918–2925.
  • Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–1512.
  • de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005.
  • Rathkopf DE, Smith MR, de Bono JS, et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol. 2014;66(5):815–825.
  • Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152–160.
  • de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–1154.
  • Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–433.
  • Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–1197.
  • Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–223.
  • Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–422.
  • Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378(15):1408–1418.
  • Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378(26):2465–2474.
  • Fizazi K, Shore N, Tammela TL, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019;380(13):1235–1246.
  • Moreira DM, Howard LE, Sourbeer KN, et al. Predictors of time to metastasis in castration-resistant prostate cancer. Urology. 2016;96:171–176.
  • Droz JP, Efstathiou E, Yildirim A, et al. First-line treatment in senior adults with metastatic castration-resistant prostate cancer: a prospective international registry. Urol Oncol. 2016;34(5):234.e21–9.
  • Akaza H, Procopio G, Pripatnanont C, et al. Metastatic castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy: treatment patterns from the PROXIMA prospective registry. JGO. 2018;4:1–12.
  • Banefelt J, Liede A, Mesterton J, et al. Survival and clinical metastases among prostate cancer patients treated with androgen deprivation therapy in Sweden. Cancer Epidemiol. 2014;38(4):442–447.
  • Westgeest HM, Uyl-de Groot CA, van Moorselaar RJA, et al. Differences in trial and real-world populations in the Dutch Castration-resistant Prostate Cancer Registry. Eur Urol Focus. 2018;4(5):694–701.
  • Aly M, Clements M, Weibull CE, et al. Poor follow-up after elevated prostate-specific antigen tests: a population-based cohort study. Eur Urol Focus. 2019;5(5):842–848.
  • Nakabayashi M, Hayes J, Taplin ME, et al. Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease. Cancer. 2013;119(16):2990–2998.
  • Tomic K, Sandin F, Wigertz A, et al. Evaluation of data quality in the National Prostate Cancer Register of Sweden. Eur J Cancer. 2015;51(1):101–111.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.